Lugano, Switzerland and Woodcliff Lake, NJ, USA, December 9, 2013 – Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigation al oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA) for prevention of acute and delayed chemotherapy–induced nausea and vomiting (CINV) following both highly and moderately emetogenic chemotherapy.
